AWARD
A -- Surveillance of Acutely Ill Adults with Respiratory Viruses, including SARS-CoV-2
- Notice Date
- 8/30/2022 1:21:08 PM
- Notice Type
- Award Notice
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- CDC OFFICE OF ACQUISITION SERVICES ATLANTA GA 30333 USA
- ZIP Code
- 30333
- Solicitation Number
- 75D30122C14944
- Archive Date
- 09/14/2022
- Point of Contact
- Mark Draluck, Phone: 7704880938, Pellumbeshe Hoxhaj
- E-Mail Address
-
syq1@cdc.gov, kfx2@cdc.gov
(syq1@cdc.gov, kfx2@cdc.gov)
- Award Number
- 75D30122C14944
- Award Date
- 08/30/2022
- Awardee
- Vanderbilt University Medical Center TN 37232-0011 USA
- Award Amount
- 49995944.00
- Description
- CDC awarded contract 75D30122C14944 to Vanderbilt University Medical Center, 1161 21st Ave S STE D3300 MCN, Nashville, TN 37232 on 30 August 2022, in the amount of $49,995,944.00. This contract provides a contractor-coordinated observational, multicenter, health surveillance network of no fewer than fifteen (15) and no more than thirty (30) nationally recognized healthcare facilities (hospitals, medical centers, universities) to conduct surveillance of COVID-19, influenza, and respiratory syncytial virus (RSV) among patients hospitalized with acute respiratory illness (ARI).� The primary objective of this effort is evaluating and monitoring vaccine effectiveness (VE) against COVID-19 and influenza-associated hospitalizations. As respiratory syncytial virus (RSV) vaccines become available, the network will also evaluate and monitor VE against RSV-associated hospitalizations. Vaccine effectiveness estimates will include effectiveness against emerging variants of concern and duration of protection. These efforts will help CDC understand vaccine failures, severe ARI, severity scores, susceptibility to infection, and mechanisms of disease attenuation. Work also includes evaluating potential therapeutics on outcomes such as ICU admission, length of hospital stay, and death resulting from COVID-19, RSV and influenza. The period of performance is for a 1-year base period from 1 September 2022 through 31 August 2023 followed by 2 1-year option periods.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/5ca9d7f39e244c09bb29111581a40ced/view)
- Place of Performance
- Address: Nashville, TN 37232, USA
- Zip Code: 37232
- Country: USA
- Record
- SN06445451-F 20220901/220830230119 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |